Correlation Analysis and Prognostic Impacts of Biological Characteristics in Elderly Patients with Acute Myeloid Leukemia
Fengli Li,Na Li,Anyou Wang,Xin Liu
DOI: https://doi.org/10.2147/cia.s375000
IF: 3.829
2022-08-08
Clinical Interventions in Aging
Abstract:Fengli Li, 1 Na Li, 2 Anyou Wang, 1, 2 Xin Liu 1, 2 1 Department of Hematology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, People's Republic of China; 2 Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China Correspondence: Xin Liu, Department of Hematology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Lujiang Road No. 17, Hefei, 230001, People's Republic of China, Tel/Fax +86-551-62283863, Email Anyou Wang, Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei, 230001, People's Republic of China, Tel/Fax +86-551-62283863, Email Background: The significant heterogeneity of elderly AML patients' biological features has caused stratification difficulties and adverse prognosis. This paper did a correlation study between their genetic mutations, clinical features, and prognosis to further stratify them. Methods: 90 newly diagnosed elderly acute myeloid leukemia (AML) patients (aged ≥ 60 years) who detected genetic mutations by next-generation sequencing (NGS) were enrolled between April 2015 and March 2021 in our medical center. Results: A total of 29 genetic mutations were identified in 82 patients among 90 cases with a frequency of 91.1%. DNMT3A, BCOR, U2AF1, and BCORL1 mutations were unevenly distributed among different FAB classifications ( p < 0.05). DNMT3A, IDH2, NPM1, FLT3-ITD, ASXL1, IDH1, SRSF2, BCOR, NRAS, RUNX1, U2AF1, MPO, and WT1 mutations were distributed differently when an immunophenotype was expressed or not expressed ( p < 0.05). NPM1 and FLT3-ITD had higher mutation frequencies in patients with normal chromosome karyotypes than abnormal chromosome karyotypes ( p < 0.001, p =0.005). DNMT3A and NRAS mutations predicted lower CR rates. DNMT3A, TP53, and U2AF1 mutations were related to unfavorable OS. TET2 mutation with CD123+, CD11b+ or CD34- predicted lower CR rate. IDH2+/CD34- predicted lower CR rate. ASXL1+/CD38+ and SRSF2+/CD123- predicted shorter OS. Conclusion: The study showed specific correlations between elderly AML patients' genetic mutations and clinical features, some of which may impact prognosis. Keywords: elderly AML, genetic mutation, FAB subtype, karyotype, immunophenotype, prognosis Acute myeloid leukemia is a malignant tumor of myeloid cells derived from bone marrow. Recent surveys show that the initiation and progression of AML are often related to genetic mutations that control multiple functions. For example, FLT3 and KIT promote the proliferation and survival of malignant cells. CEBPA, RUNX1, and NPM1 impair the differentiation and apoptosis of hematopoietic cells. DNMT3A, TET2, IDH1, and IDH2 regulate the epigenetic mechanism. NPM1, CEBPA, and GATA2 mutations predict favorable prognosis, FLT3-ITD, RUNX1, ASXL1, MLL, TP53, PHF6, and U2AF1 mutations predict adverse prognosis, especially FLT3-ITD, ASXL1, RUNX1, and TP53 mutations predict adverse prognosis under certain conditions. 1–14 The Morphologic-Immunologic-Cytogenetic classification (MIC classification) is used to make a definitive diagnosis of AML. Many studies have focused on the correlation between MIC classification and prognosis. For example, karyotype analysis based on cytogenetics as an important reference marker for prognosis has been written into National Comprehensive Cancer Network (NCCN) and European Leukemia Net (ELN) guidelines. 15,16 Among the common immunophenotypes of AML, CD19, CD38, and MPO are the immunophenotypes reported in the literature to be of favorable prognosis. 17–20 The immunophenotypes that predict adverse prognosis include CD7, CD11b, CD34, CD56, and CD123. 21–28 CD13, CD33, and CD117, which are particularly important for the diagnostic classification of AML patients, and their relations with prognosis are currently inconclusive. 21 CD14 and CD64 are mainly expressed in M4 and M5 subtypes, 29,30 and their associations with prognosis have been less reported. However, the MIC classification alone cannot effectively and accurately predict the prognosis. It also needs to be analyzed in conjunction with the genetic mutations of the patients. AML is a senile disease (median age at diagnosis is 65–70 years). 31 Unlike the precise current stratification of young and middle-aged AML patients, the clinical treatment of elderly patients is still ineffective, and their prognosis is adverse. 32 In this paper, we did -Abstract Truncated-
geriatrics & gerontology,gerontology